At Rush University Medical Center, we are putting your safety first. For information about COVID-19, see the latest updates. Rush accepts donations to support our response effort, staff, and patients and families.
Primary Sclerosing Cholangitis Treatment Study
The purpose of this study is to see if an investigational drug, GS-9674, slows the scarring process in subjects with primary sclerosing cholangitis (PSC). Study participants will be randomly assigned to receive either study drug or placebo. Participants and the study staff will both be blinded to the assignment. Study participation will last approximately two years and will involve liver biopsies, radiology testing, and regular clinic visits.
In order to participate you must meet the following criteria:
- Are between 18 and 70 years of age.
- Have a confirmed diagnosis of large duct PSC.
- Avoid getting pregnant or getting someone pregnant for the duration of the study.
- Are willing to undergo 2 liver biopsies.
This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.